Page last updated: 2024-12-08
5'-o-dimethyltritylthymidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 162419 |
| CHEMBL ID | 3143147 |
| SCHEMBL ID | 1775528 |
| MeSH ID | M0091171 |
Synonyms (40)
| Synonym |
|---|
| c31h32n2o7 |
| dmtr-t |
| 1-[(2r,4s,5r)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-hydroxy-tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione |
| dimethoxytrityl-t |
| 5'-o-(4,4'-dimethoxytrityl)thymidine, 98% |
| dmt-t |
| D3566 |
| 5'-o-(4,4'-dimethoxytrityl)thymidine |
| 40615-39-2 |
| 1-[(2r,4s,5r)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione |
| thymidine, 5'-o-(bis(4-methoxyphenyl)phenylmethyl)- |
| 5'-o-(p,p'-dimethoxytrityl)thymidine |
| einecs 255-003-1 |
| 5'-o-dimethyltritylthymidine |
| AKOS015924177 |
| thymidine, 5'-o-[bis(4-methoxyphenyl)phenylmethyl]- |
| AKOS015895545 |
| J-700115 |
| UBTJZUKVKGZHAD-UPRLRBBYSA-N |
| 1-[(2r,4s,5r)-5-[[bis (4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione |
| 5'--o--(4,4'-dimethoxytrityl)thymidine |
| 5'-o-(4,4'-dimethoxytrityl)-thymidine |
| 5'--o--(4,4'-dimethyoxytrityl) thymidine |
| 5'-o-(4,4'-dimethoxytrityl) thymidine |
| SCHEMBL1775528 |
| W-200841 |
| 1-(2'deoxy-5'-o-[bis(4-methoxyphenyl)phenylmethyl]-b-d-lyxofuranosyl)thymine |
| CHEMBL3143147 |
| DTXSID1074961 |
| F21487 |
| DS-14583 |
| 1-((2r,4s,5r)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione , |
| EN300-1718972 |
| 1-[(2r,4s,5r)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-4-hydroxyoxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione |
| CS-0003908 |
| HY-20140 |
| 5'-o-dmt-dt |
| PD151333 |
| BP-58862 |
| 5'-o-dmt-thymidine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thymidine kinase, cytosolic | Homo sapiens (human) | IC50 (µMol) | 14.0000 | 0.0160 | 1.2105 | 3.0000 | AID210699 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleobase-containing compound metabolic process | Thymidine kinase, cytosolic | Homo sapiens (human) |
| deoxyribonucleoside monophosphate biosynthetic process | Thymidine kinase, cytosolic | Homo sapiens (human) |
| thymidine metabolic process | Thymidine kinase, cytosolic | Homo sapiens (human) |
| thymidine biosynthetic process | Thymidine kinase, cytosolic | Homo sapiens (human) |
| protein homotetramerization | Thymidine kinase, cytosolic | Homo sapiens (human) |
| DNA synthesis involved in mitotic DNA replication | Thymidine kinase, cytosolic | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Molecular Functions (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| thymidine kinase activity | Thymidine kinase, cytosolic | Homo sapiens (human) |
| protein binding | Thymidine kinase, cytosolic | Homo sapiens (human) |
| ATP binding | Thymidine kinase, cytosolic | Homo sapiens (human) |
| zinc ion binding | Thymidine kinase, cytosolic | Homo sapiens (human) |
| identical protein binding | Thymidine kinase, cytosolic | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Thymidine kinase, cytosolic | Homo sapiens (human) |
| cytosol | Thymidine kinase, cytosolic | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID213300 | Compound was evaluated for inhibitory effect against phosphorylation of [methyl-3H]dThd byThymidine Kinase 2 (TK-2);NEA = Not estimated accurately | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Acyclic nucleoside analogues as novel inhibitors of human mitochondrial thymidine kinase. |
| AID210699 | Compound was evaluated for inhibitory effect against phosphorylation of [methyl-3H]dThd by HSV-1 Thymidine kinase | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Acyclic nucleoside analogues as novel inhibitors of human mitochondrial thymidine kinase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||